Project description DEENESFRITPL Novel device to remove bubbles from IV infusion lines Air embolism is a serious complication of IV infusion as accidental bubbles enter the venous system blocking blood flow and leading to serious adverse effects for patients, or even death. Current technological solutions to this problem include electronic alarms and in-line filters which are often unsuitable and place a significant burden on healthcare providers. The EU-funded Gasgon project aims to solve this unmet clinical need through the implementation of a new form of "vent" technology. It will introduce a mechanical, in-line, automatic vent capable of removing bubbles from IV fluids regardless of position or environment. The disposable vent will do this quickly and reliably without interfering with the prescribed dose of medications. This invention represents a major advancement over current methods of managing risk in IV infusions. Show the project objective Hide the project objective Objective Over 2 billion medical intravenous (IV) infusions occur each year globally, with over 80% of inpatients receiving IV treatment. Each of these infusions carry a serious health risk – the risk that gas bubbles enter with the fluid and block blood flow in patients. Air Embolism, a potentially deadly complication of IV infusion, is a result of bubbles entering the venous system and blocking blood flow leading to serious adverse complications for patients such as Sepsis, Stroke, Brain Dysfunction and Heart Attack. In extreme cases death can occur. Gasgon Medical has built a break-through and disruptive technology to reduce risk and optimise fluid management in common medical IV treatments. Currently clinicians must intervene to remove every bubble in every infusion, a labour-intensive practice that puts a strain on healthcare resources, with wasted man-hours and reduced efficacy of the medicine dose. Technology solutions on the market include electronic alarms and in-line filters – these are unsuitable in the majority of cases and place a significant human and financial burden on healthcare providers. Our innovation, which is a new form of ‘vent’ technology, will solve this unmet clinical need. Gasgon Medical has invented the first mechanical, in-line, automatic vent capable of removing bubbles from IV fluids regardless of position or environment. Our Patent-pending disposable vent acts quickly and reliably without interrupting or reducing the prescribed dose of medications. This represents a major technology advancement over current methods of managing risk in IV infusions. Gasgon Medical can lead a €220mn IV vent opportunity bringing an exciting European innovation to the global market. This novel Gasgon vent technology has the potential to positively impact healthcare delivery and performance, leading to better patient outcomes. Fields of science medical and health sciencesclinical medicineangiologyvascular diseasesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicineneurologystroke Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator TESSEN SOLUTIONS LIMITED Net EU contribution € 50 000,00 Address Rubicon centre, bishopstown. co. cork, ireland Cork Ireland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ireland Southern South-East Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
